RT Journal Article
SR Electronic
T1 Scenario Design for Infectious Disease Projections: Integrating Concepts from Decision Analysis and Experimental Design
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.11.23296887
DO 10.1101/2023.10.11.23296887
A1 Runge, Michael C.
A1 Shea, Katriona
A1 Howerton, Emily
A1 Yan, Katie
A1 Hochheiser, Harry
A1 Rosenstrom, Erik
A1 Probert, William J.M.
A1 Borchering, Rebecca
A1 Marathe, Madhav V.
A1 Lewis, Bryan
A1 Venkatramanan, Srinivasan
A1 Truelove, Shaun
A1 Lessler, Justin
A1 Viboud, Cécile
YR 2023
UL http://medrxiv.org/content/early/2023/10/12/2023.10.11.23296887.abstract
AB Across many fields, scenario modeling has become an important tool for exploring long-term projections and how they might depend on potential interventions and critical uncertainties, with relevance to both decision makers and scientists. In the past decade, and especially during the COVID-19 pandemic, the field of epidemiology has seen substantial growth in the use of scenario projections. Multiple scenarios are often projected at the same time, allowing important comparisons that can guide the choice of intervention, the prioritization of research topics, or public communication. The design of the scenarios is central to their ability to inform important questions. In this paper, we draw on the fields of decision analysis and statistical design of experiments to propose a framework for scenario design in epidemiology, with relevance also to other fields. We identify six different fundamental purposes for scenario designs (decision making, sensitivity analysis, value of information, situational awareness, horizon scanning, and forecasting) and discuss how those purposes guide the structure of scenarios. We discuss other aspects of the content and process of scenario design, broadly for all settings and specifically for multi-model ensemble projections. As an illustrative case study, we examine the first 17 rounds of scenarios from the U.S. COVID-19 Scenario Modeling Hub, then reflect on future advancements that could improve the design of scenarios in epidemiological settings.Competing Interest StatementMCR reports stock ownership in Becton Dickinson & Co., which manufactures medical equipment used in COVID-19 testing, vaccination, and treatment. JL has served as an expert witness on cases where the likely length of the pandemic was of issue. There are no other competing interests to declare.Funding StatementKS, EH, and RB acknowledge funding from NSF COVID-19 RAPID awards DEB-2028301, DEB-2037885, DEB-2126278 and DEB-2220903. EH was supported by the Eberly College of Science Barbara McClintock Science Achievement Graduate Scholarship in Biology at the Pennsylvania State University. KY was supported by the Penn State Verne M. Willaman Distinguished Fellowship in Science and NSF Grant No. DGE1255832. HH was supported by NIGMS Grant U24GM132013. MM, SV, and BL acknowledge support from NSF Expeditions in Computing Grant CCF-1918656 and VDH Contract UVABIO610-GY23.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript